Preclinical Developments to be Highlighted: Delivery of siRNA to Bone Marrow and Proof of Concept Study Results –
Fremont, California, December 20, 2007 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates, announced today that it is scheduled to present at the JPMorgan 26th Annual Healthcare Conference on […]
Commences Phase I Clinical Trial of Proprietary siRNA Molecule in Acute Renal Failure.
Fremont, California, November 19, 2007 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that it has commenced systemic dosing in humans of its proprietary product candidate, AKIi-5, a siRNA compound discovered and […]
Fremont, California, October 9, 2007 – Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that it shall receive a milestone payment from Mitsubishi Pharma Corporation, a Japanese pharmaceutical company. The milestone payment was triggered by Mitsubishi’s initiation of screening for small molecule inhibitors for selected […]
Fremont, California, October 9, 2007 – Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that it is scheduled to present on Tuesday, November 6, 2007 at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference and the CIBC World Markets 18th Annual Healthcare Conference. […]
Quark Expands Hearing Loss Program With Novel siRNA Approaches To Noise-Induced Hearing Loss With Its First Drug Candidate, AHLi-11, For The Prevention of Chemotherapy-Induced Hearing Loss In Late Pre-IND Stage
Fremont, California, September 24, 2007 – Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that it […]
Quark’s Novel siRNA Structures Exhibit Stability and Activity in vitro
Fremont, California, August 27, 2007 – Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that the Company has filed a patent application covering a number of novel chemical modifications that confer to the siRNA molecule stability […]
Quark’s First Hearing Loss Compound, AHLi-11, Slated for IND Filing By Year-End 2007
Fremont, California, August 20, 2007 – Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that it has expanded its relationship with the State University of New York at Buffalo, Center for Hearing & […]
Quark to initiate Phase 1 trial of AKIi-5 as the first human clinical study involving the systemic delivery of siRNA
Fremont, California, August 2, 2007 – Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today the presentation of positive results from preclinical efficacy studies for its proprietary […]
London, England and Freemont, CA. July 31, 2007 – Silence Therapeutics plc and Quark Pharmaceuticals, Inc. (“Quark”), announced today an expansion of their current strategic technology licensing agreement.
In April 2005 the Companies signed an Option and Licence Agreement, which provided Quark with access to Silence Therapeutics’ novel proprietary siRNA technology, AtuRNAi. The first outcome of […]